Role of inflammation in depression: Implications for phenomenology, pathophysiology and treatment

Inflammation in Psychiatry

Volumn 28, Issue , 2013, Pages 33-48

  Raison, Charles L ^a   Miller, Andrew H ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925699814     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000343966     Document Type: Chapter

References (144)

1. Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25-46.
2. Irwin MR, Miller AH: Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007;21:374-383.
3. Blume J, Douglas SD, Evans DL: Immune suppression and immune activation in depression. Brain Behav Immun 2011;25:221-229.
4. Clark J, Vagenas P, Panesar M, Cope AP: What does tumour necrosis factor excess do to the immune system long term? Ann Rheum Dis 2005;64(suppl 4):iv70-iv76.
5. Zorilla E, Luborsky L, McKay J, Roesnthal R, et al: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001;15:199-226.
6. Dowlati Y, Herrmann N, Swardfager W, et al: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
7. Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-186.
8. Haroon E, Raison CL, Miller AH: Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012;37:137-162.
9. Bower JE, Ganz PA, Aziz N, Fahey JL: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604-611.
10. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA: Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002;90:1279-1283.
11. Alesci S, Martinez PE, Kelkar S, et al: Major depression is associated wwith significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005;90:2522-2530.
12. Motivala SJ, Sarfatti A, Olmos L, Irwin MR: Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005;67:187-194.
13. Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-741.
14. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22:370-379.
15. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006;36:37-43.
16. Benedetti F, Lucca A, Brambilla F, Colombo C, Smeraldi E: Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog Neuro-Psychopharmacol Biol Psychiatry 2002;26:1167-1170.
17. Harley J, Luty S, Carter J, Mulder R, Joyce P: Elevated C-reactive protein in depression: a predictor of good longterm outcome with antidepressants and poor outcome with psychotherapy. J Psychopharmacol 2010;24:625-626.
18. Reichenberg A, Yirmiya R, Schuld A, et al: Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
19. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD: Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008;63:1022-1029.
20. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD: Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009;66:407-414.
21. Eisenberger NI, Inagaki TK, Mashal NM, Irwin MR: Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun 2010;24:558-563.
22. Raison CL, Demetrashvili M, Capuron L, Miller AH: Neuropsychiatric side effects of interferon-alpha: recognition and management. CNS Drugs 2005;19:1-19.
23. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH: Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 2009;119:181-185.
24. Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344: 961-966.
25. Raison CL, Woolwine BJ, Demetrashvili MF, et al: Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007;25:1163-1174.
26. Kraus MR, Schafer A, Schottker K, et al: Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008;57:531-536.
27. Hauser P, Khosla J, Aurora H, et al: A prospective study of the incidence and open-label treatment of interferoninduced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947.
28. Kendler KS, Gardner CO: Dependent stressful life events and prior depressive episodes in the prediction of major depression: the problem of causal inference in psychiatric epidemiology. Arch Gen Psychiatry 2010;67:1120-1127.
29. Bierhaus A, Wolf J, Andrassy M, et al: A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003;100:1920-1925.
30. Pace TW, Mletzko TC, Alagbe O, et al: Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006;163:1630-1633.
31. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH: Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010;35:2617-2623.
32. Brown DW, Anda RF, Tiemeier H, et al: Adverse childhood experiences and the risk of premature mortality. Am J Prev Med 2009;37:389-396.
33. Johnson JD, Campisi J, Sharkey CM, et al: Catecholamines mediate stressinduced increases in peripheral and central inflammatory cytokines. Neuroscience 2005;135:1295-1307.
34. Mazzeo RS, Donovan D, Fleshner M, et al: Interleukin-6 response to exercise and high-altitude exposure: influence of alpha-adrenergic blockade. J Appl Physiol 2001;91:2143-2149.
35. Tracey KJ: Reflex control of immunity. Nat Rev Immunol 2009;9:418-428.
36. O'Mahony C, van der Kleij H, Bienenstock J, Shanahan F, O'Mahony L: Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. Am J Physiol Regul Integr Comp Physiol 2009;297:R1118-R1126.
37. Frasure-Smith N, Lesperance F, Irwin MR, Talajic M, Pollock BG: The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain Behav Immun 2009;23:1140-1147.
38. Thayer JF, Fischer JE: Heart rate variability, overnight urinary norepinephrine and C-reactive protein: evidence for the cholinergic anti-inflammatory pathway in healthy human adults. J Intern Med 2009;265:439-447.
39. Raison CL, Woolwine BJ, Demetrashvili MF, et al: Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharm Ther 2007;25:1163-1174.
40. Bull SJ, Huezo-Diaz P, Binder EB, et al: Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009;14:1095-1104.
41. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG: Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009;65:344-348.
42. Raison CL, Borisov AS, Majer M, et al: Activation of central nervous system inflammatory pathways by interferonalpha: relationship to monoamines and depression. Biol Psychiatry 2009;65: 296-303.
43. Juengling FD, Ebert D, Gut O, et al: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000;152:383-389.
44. Capuron L, Pagnoni G, Demetrashvili MF, et al: Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007;32:2384-2392.
45. Felger JC, Alagbe O, Hu F, et al: Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokineinduced depression. Biol Psychiatry 2007;62:1324-1333.
46. McKinney WT Jr, Eising RG, Moran EC, Suomi SJ, Harlow HF: Effects of reserpine on the social behavior of rhesus monkeys. Dis Nerv Syst 1971;32:735-741.
47. Qin L, Wu X, Block ML, et al: Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007;55:453-462.
48. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B: Microglial activationmediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002;81:1285-1297.
49. Pemberton LA, Kerr SJ, Smythe G, Brew BJ: Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res 1997;17:589-595.
50. Fujigaki H, Saito K, Fujigaki S, et al: The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factorkappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 2006;139:655-662.
51. Huang L, Baban B, Johnson BA 3rd, Mellor AL: Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 2010;29:133-155.
52. Bonaccorso S, Marino V, Puzella A, et al: Increased depressive ratings in patients with hepatitis C receiving interferonalpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
53. Capuron L, Neurauter G, Musselman DL, et al: Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-914.
54. O'Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N, Kelley KW, Dantzer R: Lipopolysaccharideinduced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009;14:511-522.
55. Schwarcz R, Pellicciari R: Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002;303:1-10.
56. Raison CL, Dantzer R, Kelley KW, et al: CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403.
57. Zhu CB, Blakely RD, Hewlett WA: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006;31:2121-2131.
58. Felger JC, Alagbe O, Pace TW, et al: Early activation of p38 mitogen activated protein kinase is associated with interferonalpha-induced depression and fatigue. Brain Behav Immun 2011;25:1094-1098.
59. Moron JA, Zakharova I, Ferrer JV, et al: Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003;23:8480-8488.
60. Bezzi P, Domercq M, Brambilla L, et al: CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4:702-710.
61. Pitt D, Nagelmeier IE, Wilson HC, Raine CS: Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 2003;61:1113-1120.
62. Volterra A, Meldolesi J: Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 2005;6:626-640.
63. Tilleux S, Hermans E: Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007;85:2059-2070.
64. Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H: Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008;432:232-236.
65. Hardingham GE, Fukunaga Y, Bading H: Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002;5:405-414.
66. Haydon PG, Carmignoto G: Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 2006;86:1009-1031.
67. Matute C, Domercq M, Sanchez-Gomez MV: Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006;53:212-224.
68. Rajkowska G, Miguel-Hidalgo JJ: Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007;6:219-233.
69. Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59: 1116-1127.
70. Barrientos RM, Sprunger DB, Campeau S, et al: Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience 2003;121:847-853.
71. Ben Menachem-Zidon O, Goshen I, Kreisel T, et al: Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolation-induced impairment in memory and neurogenesis. Neuropsychopharmacology 2008;33:2251-2262.
72. Koo JW, Duman RS: IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008;105:751-756.
73. Kenis G, Prickaerts J, van Os J, et al: Depressive symptoms following interferon-alpha therapy: mediated by immune-induced reductions in brainderived neurotrophic factor? Int J Neuropsychopharmacol 2011;14:247-253.
74. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.
75. Pariante CM, Lightman SL: The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008;31:464-468.
76. Besedovsky HO, del Rey A: Immuneneuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996;17:64-102.
77. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH: Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003;160: 1342-1345.
78. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH: Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 2010;15:535-547.
79. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D: Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994-1000.
80. Spiegel D, Giese-Davis J, Taylor CB, Kraemer H: Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology 2006;31:1231-1244.
81. Pariante CM: Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004;7:209-219.
82. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E: Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993;150:1189-1193.
83. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006;36:37-43.
84. Pace TW, Hu F, Miller AH: Cytokineeffects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007;21:9-19.
85. Hu F, Pace TW, Miller AH: Interferonalpha inhibits glucocorticoid receptormediated gene transcription via STAT5 activation in mouse HT22 cells. Brain Behav Immun 2009;23:455-463.
86. Smoak KA, Cidlowski JA: Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Age Dev 2004;125:697-706.
87. Wang X, Wu H, Miller AH: Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol Psychiatry 2004;9:65-75.
88. Engler H, Bailey MT, Engler A, Stiner-Jones LM, Quan N, Sheridan JF: Interleukin-1 receptor type 1-deficient mice fail to develop social stress-associated glucocorticoid resistance in the spleen. Psychoneuroendocrinology 2008;33: 108-117.
89. Pariante CM, Pearce BD, Pisell TL, et al: The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 1999;140:4359-4366.
90. Quan N, Avitsur R, Stark JL, et al: Social stress increases the susceptibility to endotoxic shock. J Neuroimmunol 2001;115:36-45.
91. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353:1711-1723.
92. Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP: Glucocorticoid receptor (GR) beta has intrinsic, GRalphaindependent transcriptional activity. Biochem Biophys Res Commun 2009;381:671-675.
93. Capuron L, Pagnoni G, Demetrashvili MF, et al: Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007;32:2384-2392.
94. Juengling FD, Ebert D, Gut O, et al: Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000;152:383-389.
95. Mentis MJ, McIntosh AR, Perrine K, et al: Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 2002;159:746-754.
96. Spetsieris PG, Moeller JR, Dhawan V, Ishikawa T, Eidelberg D: Visualizing the evolution of abnormal metabolic networks in the brain using PET. Comput Med Imaging Graph 1995;19:295-306.
97. Eidelberg D, Moeller JR, Dhawan V, et al: The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14: 783-801.
98. Wichmann T, DeLong MR: Oscillations in the basal ganglia. Nature 1999;400: 621-622.
99. Feigin A, Fukuda M, Dhawan V, et al: Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001;57:2083-2088.
100. Bersano A, Aghemo A, Rumi MG, Ballabio E, Candelise L, Colombo M: Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur J Intern Med 2008;19:370-371.
101. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR: Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010;68:748-754.
102. Carter CS, Braver TS, Barch DM, Botvinick MM, Noll D, Cohen JD: Anterior cingulate cortex, error detection, and the online monitoring of performance. Science 1998;280:747-749.
103. Capuron L, Pagnoni G, Demetrashvili M, et al: Anterior cingulate activation and error processing during interferonalpha treatment. Biol Psychiatry 2005;58:190-196.
104. Paulus MP, Feinstein JS, Simmons A, Stein MB: Anterior cingulate activation in high trait anxious subjects is related to altered error processing during decision making. Biol Psychiatry 2004;55:1179-1187.
105. Eisenberger NI, Lieberman MD, Satpute AB: Personality from a controlled processing perspective: an fMRI study of neuroticism, extraversion, and selfconsciousness. Cogn Affect Behav Neurosci 2005;5:169-181.
106. Ursu S, Stenger VA, Shear MK, Jones MR, Carter CS: Overactive action monitoring in obsessive-compulsive disorder: evidence from functional magnetic resonance imaging. Psychol Sci 2003;14: 347-353.
107. Harrison NA, Brydon L, Walker C, et al: Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009;66:415-422.
108. Slavich GM, Way BM, Eisenberger NI, Taylor SE: Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci USA 2010;107:14817-14822.
109. Eisenberger NI, Lieberman MD: Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn Sci 2004;8:294-300.
110. Miller AH: Mechanisms of cytokineinduced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 2009;23: 149-158.
111. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008;64: 461-467.
112. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS: The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009;30: 497-521.
113. de Paiva VN, Lima SN, Fernandes MM, Soncini R, Andrade CA, Giusti-Paiva A: Prostaglandins mediate depressive-like behaviour induced by endotoxin in mice. Behav Brain Res 2010;215:146-151.
114. Teeling JL, Cunningham C, Newman TA, Perry VH: The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: implications for a role of COX-1. Brain Behav Immun 2010;24:409-419.
115. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N: Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006;21:227-231.
116. Muller N, Schwarz MJ, Dehning S, et al: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684.
117. Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA: Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010;35:2510-2520.
118. Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2: 717-726.
119. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-2588.
120. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001;166:7527-7533.
121. Si Q, Cosenza M, Kim MO, et al: A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol 2004;10:284-292.
122. Alano CC, Kauppinen TM, Valls AV, Swanson RA: Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006;103:9685-9690.
123. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT: Antidepressantlike actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:380-386.
124. Henry CJ, Huang Y, Wynne A, et al: Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 2008;5:15.
125. Hutchinson MR, Coats BD, Lewis SS, et al: Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008;22:1178-1189.
126. Hutchinson MR, Northcutt AL, Chao LW, et al: Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun 2008;22:1248-1256.
127. Habibi-Asl B, Hassanzadeh K, Charkhpour M: Central administration of minocycline and riluzole prevents morphineinduced tolerance in rats. Anesth Analg 2009;109:936-942.
128. Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS: Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci USA 2010;107: 2669-2674.
129. Nadjar A, Bluthe RM, May MJ, Dantzer R, Parnet P: Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 2005;30: 1492-1499.
130. Dhillon N, Aggarwal BB, Newman RA, et al: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14: 4491-4499.
131. Godbout JP, Berg BM, Krzyszton C, Johnson RW: Alpha-tocopherol attenuates NFkappaB activation and proinflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. J Neuroimmunol 2005;169: 97-105.
132. Lu X, Ma L, Ruan L, et al: Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 2010;7:46.
133. O'Connor JC, Lawson MA, Andre C, et al: Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009;182:3202-3212.
134. Potter MC, Elmer GI, Bergeron R, et al: Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 2010;35:1734-1742.
135. Katz JB, Muller AJ, Prendergast GC: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008;222:206-221.
136. Rohrig UF, Awad L, Grosdidier A, et al: Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2010;53:1172-1189.
137. Volgraf M, Lumb JP, Brastianos HC, et al: Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol 2008;4:535-537.
138. Di Pucchio T, Danese S, De Cristofaro R, Rutella S: Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opin Ther Pat 2010;20:229-250.
139. Stone TW: Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin Investig Drugs 2001;10: 633-645.
140. Pace TW, Negi LT, Adame DD, et al: Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology 2009;34:87-98.
141. Pace TW, Negi LT, Sivilli TI, et al: Innate immune, neuroendocrine and behavioral responses to psychosocial stress do not predict subsequent compassion meditation practice time. Psychoneuroendocrinology 2010;35:310-315.
142. Pace TW, Negi LT, Dodson-Lavelle B, et al: Engagement with cognitively-based compassion training is associated with reduced salivary C-reactive protein from before to after training in foster care program adolescents. Psychoneuroendocrinology 2012, E-pub ahead of print.
143. Creswell JD, Irwin MR, Burklund LJ, et al: Mindfulness-based stress reduction training reduces loneliness and proinflammatory gene expression in older adults: a small randomized controlled trial. Brain Behav Immun 2012;26: 1095-1101.
144. Black DS, Cole SW, Irwin MR, et al: Yogic meditation reverses NF-kappaB and IRF-related transcriptome dynamics in leukocytes of family dementia caregivers in a randomized controlled trial. Psychoneuroendocrinology 2012, Epub ahead of print.